Press release
Investigation for Investors in BioAtla, Inc. (NASDAQ: BCAB) over potential Wrongdoing announced
An investigation on behalf of investors in BioAtla, Inc. (NASDAQ: BCAB) shares over potential wrongdoing at BioAtla, Inc.
Investors who purchased shares of BioAtla, Inc. (NASDAQ: BCAB) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain BioAtla, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. reported that its Net Loss increased from $95.4 million in 2021 to $106.48 million in 2022.
Shares of BioAtla, Inc. (NASDAQ: BCAB) declined from $4.31 per share in February 2023 to as low as $1.42 per share in October 2023.
Those who purchased shares of BioAtla, Inc. (NASDAQ: BCAB) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for Investors in BioAtla, Inc. (NASDAQ: BCAB) over potential Wrongdoing announced here
News-ID: 3531401 • Views: …
More Releases from Shareholders Foundation, Inc.
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for BioAtla
Leading companies in this space include Aadi Bioscience, Acrotech Biopharma, ADC …
Among the 7MM countries, the total Chondrosarcoma Market Size in the United States was ~USD 8.5 million in 2023 and is aniticipated to grow with a significant CAGR during the forecast period (2024-2034).
Emerging therapies like INBRX-109, TIBSOVO (ivosidenib), and others are anticipated to drive growth in the Chondrosarcoma market over the coming years.
DelveInsight's newly released report, "Chondrosarcoma - Market Insights, Epidemiology, and Market Forecast 2034", provides a comprehensive overview of…
Synovial Sarcoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, …
DelveInsight's, "Synovial Sarcoma- Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Synovial Sarcoma pipeline includes over 15 major…
Chondrosarcoma Market: Epidemiology, Therapies, Companies, DelveInsight | Aadi B …
Chondrosarcoma Companies are Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, ENB Therapeutics LLC, Epizyme Inc, Horizon Therapeutics Plc, Incyte Corp, Inhibrx Inc, Iovance Biotherapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Les Laboratoires Servier SAS,…
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveIns …
The Osteosarcoma market is steadily advancing, driven by evolving treatment strategies and ongoing research. DelveInsight's latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics.
DelveInsight's "Osteosarcoma - Market Insight, Epidemiology, And Market Forecast - 2032 [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] report offers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United…
Investigation announced for Investors who lost money with shares of BioAtla, Inc …
An investigation was announced for investors of BioAtla, Inc. (NASDAQ: BCAB) shares over potential securities laws violations by BioAtla, Inc. in connection with certain financial statements.
Investors who purchased shares of BioAtla, Inc. (NASDAQ: BCAB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of BioAtla, Inc.…
Synovial Sarcoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging The …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 14+ key pharma and biotech companies are working on 14+ pipeline drugs in the Synovial Sarcoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Synovial Sarcoma Pipeline Insight, 2023" report…
